Athira

Athira Pharma to Participate in Upcoming June Conferences

Retrieved on: 
Wednesday, May 29, 2024
Athira

BOTHELL, Wash., May 29, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in June.

Key Points: 
  • BOTHELL, Wash., May 29, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in June.
  • Live webcasts of the fireside chats can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • An archived replay of the webcasts will be available for at least 30 days following the event.

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Retrieved on: 
Wednesday, November 29, 2023
Sidoti, Conference, Athira Pharma, Athira

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023.

Key Points: 
  • BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023.
  • Details are as follows:
    A live webcast of the presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • Athira Pharma will also host virtual one-on-one meetings with investors on Wednesday, December 6 and Thursday, December 7.
  • To register for the conference and schedule a one-on-one meeting, please visit

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, November 9, 2023
ACT, Walter, Investment, Neuromuscular junction, Patient, Pathology, Conference, Cognition, R, ADAS, Inflammation, AFL, Society, Glial fibrillary acidic protein, Food, Toxicity, HGF, IND, Administration, GFAP, Excitotoxicity, Alzheimer's disease, G&A, Microglia, Communication, Neuroinflammation, Athira Pharma, Research and development, Brain cell, Biomarker, Riluzole, ALS, Frontotemporal dementia, Washington Convention Center, Drug development, AAIC, Enzyme inhibitor, Plasma, Mouse, Doctor of Philosophy, FDA, Neurodegenerative disease, Survival, Central nervous system, GST, Fine chemical, Pharmaceutical industry, Medical imaging, Cryptocurrency, Neuroscience, Athira

BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.
  • R&D expenses were $27.2 million for the quarter ended September 30, 2023, compared with $17.0 million for the quarter ended September 30, 2022.
  • G&A expenses were $7.8 million for the quarter ended September 30, 2023, compared with $7.2 million for the quarter ended September 30, 2022.
  • The increase was primarily due to increases in personnel expenses, partially offset by a decrease in business development expenses.

Athira Pharma to Participate in Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 8, 2023
Athira, Fireside chats, Fireside, Athira Pharma, Conference, Pharmaceutical industry, Online shopping

BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023, in London.

Key Points: 
  • BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023, in London.
  • Details are as follows:
    A live webcast of the Fireside Chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • An archived replay will be available for at least 30 days following the event.

Athira Pharma to Participate in Upcoming October Conferences

Retrieved on: 
Thursday, September 28, 2023
Athira, Athira Pharma, Conference

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in October.

Key Points: 
  • BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in October.
  • Investors interested in meeting with Athira management during the JonesTrading Conference, please reach out to your JonesTrading representative or contact Julie Rathbun at [email protected] .
  • Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • An archived replay of the webcasts will be available for at least 30 days following the event.

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Retrieved on: 
Tuesday, September 19, 2023
Athira, Athira Pharma, Conference, Pharmaceutical industry

BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City.

Key Points: 
  • BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City.
  • Details are as follows:
    Panel Presentation Date and Time: Tuesday, September 26, 2023, from 10:30 am – 11:00 am ET
    A live webcast of the panel presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • An archived replay of the webcasts will be available for at least 30 days following the event.

Athira Pharma to Participate in Upcoming June Conferences

Retrieved on: 
Wednesday, May 31, 2023
Athira, Goldman Sachs, Athira Pharma

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:

Key Points: 
  • BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:
    Presentation on Wednesday, June 14, 2023, at 8:40 a.m.PT in Dana Point, California
    Live webcasts of the Jefferies fireside chat and Goldman Sachs presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • An archived replay of the webcasts will be available for at least 30 days following the event.

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

Retrieved on: 
Monday, May 22, 2023
Athira Pharma, Morgan Stanley, Amgen, Doctor of Philosophy, Corporate development, Health care, Neurodegenerative disease, UCLA Anderson School of Management, Entertainment Services and Technology Association, AbbVie, McKinsey & Company, Business administration, Retirement, Patient, Corporation, Management, Master of Business Administration, Therapy, Chemical engineering, ALS, AOBiome, Massachusetts Institute of Technology, Pharmaceutical industry, Athira, Science

BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately.

Key Points: 
  • BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately.
  • Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira’s Chief Financial Officer for eight years.
  • Most recently, he served as the Chief Business Officer at Cyteir Therapeutics, where he was an integral part of the leadership team that took the company public.
  • In addition to these leadership positions, Mr. Gengos also held the Chief Financial Officer and Chief Business Officer roles at AOBiome Therapeutics and was the Chief Operating Officer and Head of Corporate Development at Synlogic, Inc.

Athira Pharma to Participate in Upcoming May Investor Conferences

Retrieved on: 
Monday, May 8, 2023
Athira, Webcast, Athira Pharma

BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor conferences:

Key Points: 
  • BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor conferences:
    Fireside chat on Monday, May 15, 2023, at 10:30 am ET in New York.
  • A live webcast of the JMP Securities presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • An archived replay of the webcast will be available for at least 30 days following the event.

Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences

Retrieved on: 
Wednesday, March 8, 2023
Fireside, EDT, Fireside chats, Webcast, Athira Pharma, Research, Athira, Biotechnology, Stifel, Fine chemical

BOTHELL, Wash., March 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira’s management team will participate in the following upcoming investor conferences:

Key Points: 
  • BOTHELL, Wash., March 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira’s management team will participate in the following upcoming investor conferences:
    Needham Neurosciences Investor Forum taking place virtually March 15, 2023.
  • Ami Fadia, biotechnology equity research analyst with Needham & Co., will lead a Fireside Chat with the Athira management team at 10:50 a.m. EDT.
  • Paul Matteis, biotechnology equity research analyst with Stifel, will lead a Fireside Chat with the Athira management team on Tuesday, March 28 at 2:30 p.m. EDT.
  • Live webcasts of both presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .